Items tagged with Treatment
Activists interrupt TB conference opening ceremony to call on J&J to cut price of TB drug in half, to one dollar per day (post with simple image)
Activists demand that Johnson & Johnson cut the price of bedaquiline in half, to no higher than $1 per day—$32 per person per month—double the price that researchers estimate bedaquiline could be sold for a profit.
Urgent need to address the Global Fund procurement cliff for TB (post with simple image)
Activists urge the Global Fund and donors to take prompt action to address the grave risks posed to countries that are rapidly shifting from pooled procurement of TB medicines and commodities.
HIV and TB treatment at risk as countries gradually lose Global Fund support (post with simple image)
Médecins Sans Frontières calls on Global Fund Board to make urgent changes to prevent drug stock-outs and quality issues.
Advocates call on Indian government to improve its response to drug-resistant TB (post with simple image)
Advocates call for minimizing the use of injectable agents and scaling up universal drug susceptibility testing.
WHO updates its treatment guidelines for MDR/RR-TB (post with simple image)
The updated WHO treatment guidelines recommend that drug-resistant TB be treated with oral drugs only, including newer, more potent drugs with fewer side effects.
TB activists for first time challenge TB drug patent in India (post with simple image)
TB activists for first time challenge TB drug patent in India, in bid to prevent Johnson & Johnson from extending monopoly.
TB CAB statement on safety of using bedaquiline and delamanid together (post with simple image)
Global TB CAB welcomes confirmation of safety of using bedaquiline and delamanid together, urges uptake.
TAG statement on FDA priority review of pretomanid (post with simple image)
Statement from Treatment Action Group on FDA priority peview of TB Alliance’s new anti-TB drug pretomanid.
MSF: Johnson & Johnson should make TB drug available for all at $1/day (post with simple image)
MSF protests at J&J’s annual shareholders meeting to demand a say in how lifesaving TB drug developed with considerable joint efforts, including public funding and MSF operational research, will be made available and affordable.
Ad-hoc donations of bedaquiline threaten sustainable, affordable access for patients (post with simple image)
Advocates call on Indian Minister of Health to discontinue and phase out the drug donations of bedaquiline offered by Johnson & Johnson.
Page 91 of 95 · Total posts: 0←First 90 91 92 Last→